What are the reported side effects of Cerebrolysin?

Reported side effects of Cerebrolysin include: Injection site pain (IM route), Hyperthermia / fever (rare, higher doses), Agitation or anxiety (uncommon), Nausea, Headache (transient), Allergic reaction (rare — porcine-derived, avoid in pork allergy), Seizure risk at very high doses in predisposed individuals.

Nootropic

Cerebrolysin

Q: What is the dosing range for Cerebrolysin?

Cerebrolysin is typically dosed at 5mL (low), 10mL (moderate), or 30mL (high) mL, administered Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access. These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

Also known as: FPF 1070, EBEWE Cerebrolysin, Brain-derived peptide mixture

Cerebrolysin is a prescription pharmaceutical in many European and Asian countries. It is not FDA-approved in the United States. Research use only in the US. For informational purposes only.

📚 Content aggregated from:3 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

Cerebrolysin is a brain-derived peptide mixture produced by controlled enzymatic breakdown of porcine brain proteins. Unlike synthetic peptides, it is a complex of ~25% low-molecular-weight neuropeptides and ~75% free amino acids, with the bioactive peptide fraction mimicking the endogenous neurotrophic factors BDNF, NGF, GDNF, and CNTF in their mechanisms. It has a 30+ year clinical history in Eastern Europe and Asia for stroke recovery, traumatic brain injury, Alzheimer's disease, and vascular dementia — with a substantial human trial database.

Research Summary

Cerebrolysin's neuroprotective effects have been demonstrated in over 100 clinical trials, though most are from Eastern European and Asian centers with varying methodological quality. The CACTUS trial (N=256, multicenter) showed significant improvement in cognitive outcomes after ischemic stroke vs placebo. The ARTIST trials evaluated Cerebrolysin for Alzheimer's disease with mixed results. Meta-analyses of stroke and dementia trials generally support modest-to-moderate benefit. Mechanistically, the peptide fraction upregulates BDNF/NGF signaling, reduces excitotoxicity, inhibits caspase-3, and promotes synaptogenesis in animal and in vitro models.

Dosing Range

low

5mL

moderate

10mL

high

30mL

Units: mL · Frequency: Daily for 10–20 day courses (IV preferred in clinical use); SQ/IM for research access

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Intravenous infusion (clinical standard — dilute in 100mL saline over 15–30 min)Intramuscular injection (research use — lower bioavailability)Subcutaneous injection (less common)

Reconstitution Notes

Cerebrolysin is supplied as a ready-to-use sterile solution (standard concentrations: 5mL, 10mL ampoules). For IV use, dilute in normal saline or D5W. For IM research use, can be injected undiluted. Refrigerate; do not freeze; use within 24 hours of opening ampoule.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Injection site pain (IM route)
Hyperthermia / fever (rare, higher doses)
Agitation or anxiety (uncommon)
Nausea
Headache (transient)
Allergic reaction (rare — porcine-derived, avoid in pork allergy)
Seizure risk at very high doses in predisposed individuals

Research Papers

3 peer-reviewed sources

Cerebrolysin in patients with acute ischemic stroke — CACTUS trial

Stroke2012

A systematic review of Cerebrolysin for treatment of neurodegenerative disorders

CNS Drug Reviews2015

Neurotrophic peptides in Cerebrolysin — BDNF-like and NGF-like activity

Neurochemical Research1996

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/nootropics

Extensive community experience with Cerebrolysin — IM self-administration protocols, cognitive effects, TBI recovery reports.

View original thread

r/Peptides

Research peptide community protocols — Cerebrolysin stacked with Semax, Selank for cognitive enhancement and neuroprotection.

View original thread

Overview

Cerebrolysin occupies a unique position: it is simultaneously a pharmaceutical (prescribed daily in Austria, Russia, China, South Korea, and many other countries) and a research compound outside its approved markets. With over 30 years of clinical use and a substantial — if imperfect — human trials database, it has more clinical evidence than nearly any synthetic nootropic peptide.

What's In It?

Cerebrolysin is produced by standardized enzymatic hydrolysis of porcine brain proteins. The resulting solution contains:

~25%: Low-molecular-weight neuropeptides (< 10kDa) — the bioactive fraction
~75%: Free amino acids — supporting neuropeptide and neurotransmitter synthesis

The exact peptide composition varies slightly between batches but includes fragments that mimic endogenous neurotrophic factors:

BDNF-like peptides (synaptic plasticity)
NGF-like peptides (cholinergic neuron support)
GDNF-like peptides (dopaminergic neuron support)
CNTF-like peptides (neuronal survival)

Clinical Evidence Base

Cerebrolysin has been studied more extensively than most peptides in this library:

Stroke recovery: Multiple RCTs and the multicenter CACTUS trial (2012) demonstrated improved functional outcomes and cognitive performance post-ischemic stroke compared to placebo.

Traumatic brain injury: Several trials showed accelerated functional recovery and improved neurological scores.

Alzheimer's disease: The ARTIST and subsequent trials showed modest-to-moderate cognitive improvement, with effect sizes comparable to approved cholinesterase inhibitors.

Vascular dementia: Consistent improvements in cognitive function across multiple trials.

The IV vs IM Question

Clinical trials use IV infusion (10–30mL diluted in saline, over 15–30 minutes, for 10–20 consecutive days). This provides the highest bioavailability and most reliable outcomes.

For research access without IV capability, intramuscular injection is the most common approach — typically 5mL daily for 10 days. Bioavailability via IM is lower than IV but meaningful.

Stacking

In nootropic communities, Cerebrolysin is often combined with:

Semax: Synergistic BDNF upregulation (Semax stimulates production; Cerebrolysin directly provides neurotrophic peptides)
Selank: Anxiolysis to counterbalance any stimulation
BPC-157: Systemic healing support alongside neuroregenerative focus

The Cerebrolysin + Semax combination is sometimes called the "Russian nootropic stack" and is widely discussed in longevity and biohacking communities.